The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Blackstone follows Abingworth, but why?
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
